Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Areas of unmet need in metastatic urothelial carcinoma

Robert J. Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the unmet needs of patients with metastatic urothelial carcinoma (mUC), a patient population characterized by extremely poor prognosis. Many patients with mUC do not response to chemo- or immunotherapy (IO), and those who do respond to IO inevitably relapse and require further lines of treatment. Thus, there a high unmet need for therapeutic advances for the refractory mUC population, as well non-responders. Prof. Jones emphasizes precision medicine as a means to progress in the therapeutic field to identify patients who will not benefit from conventional treatment methods, but rather targeted approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.